Background {#Sec1}
==========

Felid herpesvirus 1 (FHV-1), an alphaherpesvirus, causes upper respiratory tract disease in cats that is characterised by pyrexia, severe nasal and ocular discharge, conjunctivitis and oral ulceration. It is a common cause of necrotising upper respiratory tract infections (URI) in cats housed in shelters, with more than 50 % of cats shedding virus only one week after admission \[[@CR1]\]. The virus typically replicates in epithelial cells of the conjunctiva and the upper respiratory tract and infects local neurons, establishing latency in the trigeminal, pterygopalatine and cranial cervical ganglia \[[@CR2]\]. Although virus replication is generally limited to the upper respiratory tract and conjunctiva, viraemia has been detected during the acute phase of infection \[[@CR3], [@CR4]\] and a recent report has described a case of non-suppurative meningoencephalitis in cats, suggesting that FHV-1 has potential to cause more invasive disease \[[@CR5]\]. Vaccination has been used to help control disease caused by FHV-1 since the mid-1970s. Both attenuated and inactivated vaccines are in use currently, and while they can reduce the severity of disease, they do not prevent infection \[[@CR6]--[@CR9]\].

Early studies demonstrated that isolates of FHV-1 were antigenically indistinguishable using conventional serological techniques. Additionally, a high level of genomic homogeneity was identified using restriction endonuclease cleavage analyses \[[@CR10], [@CR11]\]. A subsequent restriction endonuclease cleavage analysis study of 78 Japanese isolates detected three FHV-1 genotypes, although these genotypes still appeared to be very similar \[[@CR12]\]. Since these early studies there has been only limited investigation of the extent of variation between vaccine and wild type strains of FHV-1.

This study aimed to use next generation sequencing to compare the genomes of contemporary Australian clinical isolates of FHV-1 to those of historical clinical isolates, including isolates that predate the introduction of live attenuated vaccines into Australia. Analysis of the genome sequences aimed to assess the level of genetic diversity, identify potential genetic markers that could influence the in vivo phenotype of the isolates and examine the sequences for evidence of recombination.

Results {#Sec2}
=======

Genome sequence analysis of 26 FHV-1 isolates {#Sec3}
---------------------------------------------

The full genome sequences of a panel of 26 FHV-1 isolates were assembled and analysed. This included 24 Australian clinical field isolates spanning nearly 40 years, as well as isolates from two currently available vaccines. The genome sequence of the prototype C-27 FHV-1 strain (GenBank:NC_013590), a historical isolate from North America, was also included in the analysis \[[@CR13]\]. The genomes of the Feligen vaccine isolate of FHV-1 assembled by two different methods (*de novo* assembly and map to reference assembly) were identical, with the exception of the regions containing short sequence repeats. This provided a high level of confidence in genome assembly by mapping to a reference sequence and this method was used for all other FHV-1 isolates in this study. Genome sequence data have been deposited into GenBank under the accession numbers as listed in Table [1](#Tab1){ref-type="table"} \[GenBank:KR296657 and GenBank:KR381779 - KR381803\]. The size of the FHV-1 full genomes ranged from 133.5 kbp (isolate 3227--05) to 135.1 kbp (isolate 3225--05). Genome length variation occurred primarily as a result of differences in the large sequence repeat regions (IRS/TRS) and in the unique short region as a result of tandem repeat iterations.Table 1FHV-1 isolates sequenced in this studyVirus IDYearOrigin^a^DiseaseSiteVaccOther^b^GenBankReference85/681968Shelter AURTINasal swabN6 mo female, febrileKR381787\[[@CR31]\]117/681968Shelter AURTINasal swabN7 woKR381780\[[@CR31]\]124/68b1968Shelter AURTINasal swabN8 yo, femaleKR381788This study135/68a1968Shelter AURTINasal swabNn/aKR381786This study221/711971PrivateURTI, conjunctEye swabN3.5 wo female PersianKR381781This study356/75b1975BlackburnURTIn/aNSiameseKR381784This study384/751975MorningtonPneumoniaLungN5 wo female BurmeseKR381782This study448/771977Privaten/aPharynx swabNn/aKR381783This study571/791979Albert ParkConjunctEye swabNMaleKR381785This study729/831983BalwynConjunctn/aY3 moKR381779This study3224/042004Shelter BURTI, oral ulcerNasal swabY4 yo male DSHKR381792This study3225/052005Shelter BAbsentEye swabY10 wo male DLHKR381801This study3226/052005Shelter BURTIOral swabY9 wo male DSHKR381793This study3227/052005Shelter BAbsentNasal swabY15 wo male DSHKR381802This study3228/052005Shelter BOral ulcerNasal swabY10 wo female DSHKR381794This study3229/052005Shelter BURTIEye swabn/a16 wo male DLHKR381795This study3230/052005Shelter BURTINasal swabY1 yo male DSHKR381796This study3231/052005Shelter BOral ulcer, conjunctOral swabY8 wo male, DLHKR381797This study3232/052005Shelter BOral ulcerEye swabY9 wo female DSHKR381798This study3233/052005Shelter BURTI, diarrheaOral swabY12 wo female DSHKR381799This study3234/052005Shelter BURTIEye swabY8 wo female DSHKR381800This study3235/062006Shelter BURTI, conjunctOral swabY5 wo male DSHKR381789This study3236/062006Shelter BURTIEye swabY4 yo male SiameseKR381791This study3238/062006Shelter BURTIOral swabY2 yo male DSHKR381790This study3239/142013USA-Vaccine-FeligenRCP VirbacKR296657-3240/142013USA-Vaccine-Companion IntervetKR381803-^a^All isolates sequenced, excluding vaccine isolates, were from Victoria, Australia^b^ *DSH* domestic short hair, *DLH* domestic long hair, *yo* year old, *mo* month old, *wo* week old, *URTI* upper respiratory tract infection, *Conjunct* conjunctivitis, *Y/N* yes/no, *n/a* data not available

Despite the long time span over which the isolates were obtained, alignment of the FHV-1 genomes (Fig. [1a](#Fig1){ref-type="fig"}) revealed that diversity between them only ranged from 0.0 to 0.01 %. While the limited geographical range of many of the Australian isolates could have influenced this, three of the genomes analysed in this study were from isolates of North American origin. The most genetically diverse isolates (135/68 from 3225/05 and 3230/05), differed genome-wide by only 83 single nucleotide polymorphisms (SNPs), while some isolates shared 100 % nucleotide identity (excluding large regions of tandem repeat reiterations). The identical viruses included 356/75 with 571/79, while the eleven 2004/2005 field isolates differed by 0 to 4 SNPs, and the three 2006 isolates differed by 1 or 2 SNPs. The two vaccines were identical (excluding large reiterative repeat regions) and so are both likely to have been derived from the widely used F2 strain. The C-27 strain, a field strain isolated contemporaneously with the F2 vaccine strain from the USA, varied from the F2-derived vaccine strains by only 5 SNPs genome-wide (excluding large reiterative repeat regions) \[[@CR14], [@CR15]\]. The non-synonymous nucleotide differences (SNPs and insertions/deletions, or indels), as indicated by predicted amino acid residue differences between isolates, are provided in Table [2](#Tab2){ref-type="table"}.Fig. 1Nucleotide sequence alignment and phylogenetic tree of the complete genomes of 27 FHV-1 isolates, excluding the terminal repeat region. **a** Alignment of the complete genome sequences of FHV-1 isolates performed using MAFFT. The Feligen vaccine F2 isolate was used as the reference sequence. Vertical black lines indicate SNPs relative to the reference and dashes indicate sequence gaps. **b** Phylogenetic tree generated from the complete genome alignment, using the Jukes Cantor model and the neighbor-joining method. One thousand bootstrap replicates were used to assess the significance of the tree topology. The bar indicates nucleotide substitutions per site. The origin of isolates is indicated to the right of the isolate nameTable 2Amino acid residue changes resulting from non-synonymous nucleotide polymorphisms, including insertions/deletions, compared to the reference isolate (F2 strain) of FHV-1GeneAA change^a^Variant isolates ^b^Unique long regionUL1F4L135/68UL3.5V15I2004/2005UL5T7I124/68, 3235/06, 3236/06, 3238/06UL13S25P85/68, 117/68, 124/68, 135/68, 221/71, 356/75, 385/75, 448/77, 571/79, 729/83,3235/06, 3236/06, 3238/06UL16F344V2004/2005UL17R519Q2004/2005UL21A48D3234/05UL25T60A2004/2005UL27P872L3235/06, 3236/06, 3238/06UL28Q427PAllUL29S1089PFieldUL30M943I3228/05, 3230/05I153T729/83UL35R3SNC_013590UL36G2503E3230/05V1310M124/68T2565M221/71N2936-135/68V2937-135/68Q2980K117/68P2838S85/68, 117/68, 124/68, 135/68, 221/71, 356/75, 385/75, 448/77, 571/79, 729/83, 3235/06, 3236/06, 3238/06UL37L866F2004/2005UL38I277MFieldUL40V66IFieldUL44E133KAllUL45R102H729/83UL49T104I3236/06UL52Y484CFieldS579I3225/05UL54I206V2004/2005S60P135/68UL55I78MFieldV1D59G124/68ICP0S412F356/75, 571/79Unique short regionUS7M165TFieldP186S124/68, 3235/06, 3236/06, 3238/06Repeat regionICP4T156N124/68, 3235/06, 3236/06, 3238/06A419V85/68, 117/68, 124/68, 135/68, 221/71, 3235/06, 3236/06, 3238/06H875Q385/75V983A356/75, 571/79, 3224/04, 3225/05, 3226/05, 3227/05, 3228/05, 3229/05, 3230/05, 3231/05, 3232/05, 3233/05, 3234/05E1034K3235/06, 3236/06, 3238/06E1054G2004/2005US1L261-85/68^a^ *AA* amino acid change^b^Relative to the vaccine isolates (F2 FHV-1 strains from the Feligen/Companion vaccines). All = Variant found in all non-vaccine isolates, Field = Variant found only in all Australian isolates sequenced in this study, 2004/2005 = Variant unique to 2004/2005 field isolates

Phylogenetic and recombination analyses of FHV-1 isolates {#Sec4}
---------------------------------------------------------

Phylogenetic analyses revealed that FHV-1 isolates fell into two main groups (Fig. [1b](#Fig1){ref-type="fig"}). Whilst some isolates with known geographical or temporal associations did cluster together (for example all 2004 and 2005 isolates), overall there was no clear relationship between viral genome sequences, the geographical location where the virus was isolated, the year of virus isolation or whether they predated the date of introduction of the attenuated FHV-1 vaccine into Australia in 1977. No clear association was detected between the genome sequence and the presence or nature of disease in the cat from which the virus was isolated.

Discussion {#Sec5}
==========

The genome sequences of Australian isolates that predated the introduction of the FHV-1 vaccine into Australia (in 1977) had a high sequence identity with isolates obtained since then, and also with isolates originating from the USA. Overall, our data demonstrated that FHV-1 genomes are highly conserved, more so than any of the other herpesviruses analysed to date, with a similar study of equine herpesvirus 1 (EHV-1) isolates finding variation of between 5 and 173 SNPs between EHV-1 isolates \[[@CR16]\]. Previous studies have suggested greater differences between FHV-1 isolates, including re-arrangements in the UL44 (gC) gene \[[@CR17]\], restriction endonuclease cleavage site differences in the UL17 gene \[[@CR18]\], and differences in *Mlu*I cleavage patterns across the genome \[[@CR11]\]. However, all the isolates examined in our study had conserved gene arrangements, with only one SNP detected in UL44 (a non-synonymous substitution), and the predicted restriction endonuclease cleavage patterns generated from the sequence data varied mainly as a result of variations in short tandem repeat iterations.

This study included analyses of fourteen FHV-1 isolates from cats housed in an animal shelter between 2004 and 2006. The cluster of viruses from this shelter in 2004 and 2005 is of particular interest because of the apparent transience of a dominant virus in a shelter environment. The SNP profile of the viruses from 2004 to 2005 was distinct from those of all the other isolates sequenced, but this pattern was not detected in the 2006 isolates from the same shelter. The close phylogenetic relationship between the viruses isolated in 2004/2005, and between those collected in 2006, suggests endemic circulation in each of these periods, with clear evidence of displacement of the 2004/2005 viruses by those detected in 2006. This displacement may have occurred as a result of increased transmissibility of the newer viruses, or management changes, such as seasonal crowding \[[@CR19]\], depopulation and repopulation of the shelter, or sampling bias (only samples free of feline calicivirus were selected for use in this study).

In vitro studies have reported a high rate of recombination in FHV-1 \[[@CR20]\]. However, no evidence of recombination was detected between the 27 FHV-1 isolates, irrespective of genomic region analysed or the program used (*P* \> 0.05). It is possible that recombination events may not have been detected because of the low levels of diversity among the viruses in our study. It is also possible that previous in vitro studies may have overestimated the likelihood of FHV-1 recombination because of the use of high multiplicities of infection and simultaneous infection, as both these factors have been shown in previous studies to increase the rate of recombination in vitro in other herpesviruses \[[@CR21]\]. Recombination would be predicted in circumstances where the opportunity for co-infection is high and where the recombinant progeny have a survival advantage over the parent viruses and dominant field strains. While infective pressure in a shelter environment would be expected to allow concurrent infections with different FHV-1 isolates, there may be insufficient selective pressure on recombinants for them to emerge and persist in vivo in a natural (shelter) environment, particularly as the low levels of diversity among FHV-1 viruses may result in insufficient selective distinction for specific viruses to emerge in a population.

Conclusions {#Sec6}
===========

Attenuated herpesvirus vaccines are used not only against FHV-1 in cats, but also against Marek's disease virus and infectious laryngotracheitis virus (ILTV) in poultry, bovine herpesvirus 1 in cattle, pseudorabies virus in swine, and EHV-1 and equine herpes virus 4 (EHV-4) in horses. Previous studies of ILTV in poultry have demonstrated that attenuated vaccine strains can participate in natural recombination events that lead to the generation of more virulent progeny \[[@CR22]\]. The risk of recombination involving other attenuated veterinary herpesvirus vaccines has not been evaluated comprehensively, but the risk appears to higher in some viruses (such as EHV-4) and lower in others (such as EHV-1) \[[@CR16]\]. The results from this study suggest that the risk for FHV-1 vaccine recombination may also be low. Although the FHV-1 genome sequencing data from this study confirms the findings of earlier studies that FHV-1 s are relatively homogeneous \[[@CR11]\] this study did detect SNPs unique to F2-derived vaccine strains, in genes UL28 and UL44. A search of all FHV-1 sequences available on GenBank identified only nine sequences covering these regions of the FHV-1 genomes, all relating to the UL44 gene. None of the sequences contained the vaccine-specific SNP, however the sequences were mostly of unknown origin apart from two; a BAC of the C-27 strain \[GenBank:GM036023\] and strain C7301 \[GenBank:D86616\]. There is the potential to use the F2-derived vaccine unique SNPs to differentiate vaccine FHV-1 isolates from other circulating FHV-1 s, and thus facilitate future epidemiological studies in FHV-1, especially to investigate the epidemiology of attenuated FHV-1 vaccines. Sequencing of more geographically diverse isolates will help confirm whether these SNPs are suitable markers for such studies.

Methods {#Sec7}
=======

Viruses and genome sequencing {#Sec8}
-----------------------------

Ten historical and fourteen recent Australian FHV-1 isolates, as well as two live attenuated vaccines currently available in Australia (Table [1](#Tab1){ref-type="table"}) were selected from our laboratory archive. Historical isolates were obtained from clinical samples submitted to our laboratory as a component of past diagnostic services. Recent samples were collected from shelter-housed cats in 2004 to 2006 with approval from the Faculty of Veterinary Science, Animal Ethics Committee at The University of Melbourne (reference number 0004055.1) and with the consent from the shelter owners. Viruses were propagated in cultures of Crandell Rees feline kidney (CRFK) cells \[[@CR23]\] for six passages, during which three plaque purifications were performed. CRFK cells are derived from a normal, female, 12 weeks old cat and are commercially available (ATCC CCL-94). Isolates selected for sequencing dating from 2004 to 2006 were all from animals that were negative for feline calicivirus, as determined by RT-PCR \[[@CR24]\]. Viral nucleocapsid genomic DNA was purified and sequenced as described previously \[[@CR16]\]. Libraries were prepared using 50 ng of viral genomic DNA with the Illumina Nextera DNA library preparation kits according to manufacturer's instructions, and loaded onto an Illumina MiSeq. Sequencing was carried out using a 300 cycle V2 SBS kit (Illumina) in paired-end format. Reads were trimmed to an error probability limit of 0.5 % and mapped against the prototype FHV-1 sequence, strain C-27 \[GenBank:NC_013590\], using medium-low sensitivity options in the bioinformatics package Geneious V6.1.7 \[[@CR25]\]. For comparison, a *de novo* assembly of the genome of the F2 strain of FHV-1 from the Feligen vaccine (Virbac) was also performed using the medium-low sensitivity settings in Geneious. The details of the sequencing metrics are provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Phylogenetic and recombination analyses {#Sec9}
---------------------------------------

Alignments of the complete genome sequences of the FHV-1 isolates, excluding the terminal repeat regions (TRS), were prepared using the Multiple Alignment with Fast Fourier Transformation (MAFFT) version 7 plugin in Geneious \[[@CR26]\]. The F2 vaccine strain of FHV-1 was used as the reference sequence. The historical C-27 strain of FHV-1 was also included throughout the analyses. Phylogenetic analyses were performed on the complete genome sequences, excluding the TRS and large sequence gaps, using the neighbor-joining method in Geneious with the Jukes Cantor model of nucleotide substitution \[[@CR27]\]. One thousand bootstrap replicates were used to assess the significance of the phylogenetic tree topology.

To detect evidence of historical recombination events between the isolates, two programs were used, SplitsTree4 \[[@CR28]\] and RDP4 \[[@CR29]\], as previously described \[[@CR16]\]. Short tandem repeat regions were identified in the aligned genomes prior to analysis using the Phobos plugin in Geneious V6.1.7. Default settings and score constraints for satellites with a maximum repeat unit length of 50 nucleotides were used. The identified repeat regions were removed from all viruses in the alignment as the methods used in this study do not allow the length of these regions to be accurately determined, and differences in the length of these regions could give rise to false positive recombination events being detected. The resultant whole genome alignments, as well as the separate UL, US and IRS genomic region alignments, were analysed for evidence of recombination. Splits network trees were generated with an uncorrected P characters transformation model, ignoring gapped sites. Other models were tested but yielded no significant topological differences. Statistical analyses of the recombination networks were performed using the Phi test as implemented in SplitsTree4 \[[@CR30]\]. In RDP4 six different methods were used to assess the sequences for recombination breakpoints, MaxChi, Bootscan, SiScan, Chimaera, GENECONV and RDP, with default RDP4 settings used throughout.

Additional file {#Sec10}
===============

Additional file 1: Table S1.FHV-1 sequencing metrics, viral genome sequence details. (DOCX 17 kb)
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